Company Overview

Update
Headquarters:
Valbonne
Funding:
$16.10M
Categories:
Biotechnology

TxCell develops cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases.

Description

Update

TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Funding Rounds (1) - $16.10M

Update

Investors (3)

Update
  • 7ef03658f51d80b60236177ba3c8d3be

    InnoBio Fund

    InnoBio is a French venture capital fund of €140 million, managed by CDC Enterprises..
  • 2b95617f483f89eda188ffd276752aff

    Auriga Partners

    Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early..
  • 7bf2eaa702d929e284a5f892270442c4

    Seventure Partners

    Venture Capital

Offices/Locations (1)

Update
  • Office

    Les Cardoulines HT1

    Allée de la Nertière, Sophia-Antipolis,

    Valbonne, 06560

    FRA